Gland Pharma Limited (GLAND) tested resistance today, gaining +5% intraday to ₹2502.1 on the NSE. The move is technical, driven by the stock hitting its 6M resistance trendline at ₹2491, though it has not yet cleared this level. Gland Pharma, a large-cap specialty and generic drug manufacturer, saw its stock price rise amid a generally positive sector momentum, though today’s move appears to be more company-specific given the resistance test.

Technical setup — trendlines & DMA

The current 6M trendline structure shows GLAND’s support floor at ₹2441, which is 2.4% below today’s price. Resistance is at ₹2491, just 0.4% below the current price, indicating the stock is testing but has not yet cleared this resistance level. The 50-DMA at ₹2072.6 is above the 200-DMA at ₹1864.8, signaling a bullish trend. However, GLAND is currently 14% above the 50-DMA, suggesting it is in an extended position. The stock is in the upper third of its 52W range, indicating much of the recent upward move may already be priced in.

Fundamentals & business context

With a PE of 38.1, GLAND’s valuation appears stretched relative to its 16.0% profit margin and 21.4% revenue CAGR over the past five years. This suggests the market may be pricing in future growth expectations, though the current earnings multiple is high given the current profitability levels. Institutional ownership stands at 36.3%, indicating a level of confidence from smart money, though the absence of a recent NSE catalyst suggests today’s move is more technically driven than fundamentally motivated.

Algorithmic scorecard

GLAND’s overall algorithmic scorecard reflects a technically strong but fundamentally weaker profile. The strongest signals include excellent revenue growth with a 21.4% CAGR and very low debt with a D/E ratio of 0.00, indicating robust financial health and growth potential. However, the weakest signals are the overvalued PEG ratio of 3.97, suggesting the stock is expensive relative to its growth rate, and the negligible dividend yield of 0.86%, offering little income to investors. These contrasting signals highlight the need for careful consideration of both growth prospects and valuation metrics.

Company outlook

Management provided forward guidance of 12% to 13% consolidated top-line growth for FY ’27, driven by new product launches, GPO contracts, and the Cenexi business. They expect mid-teen EBITDA levels in the midterm for Cenexi and a CAGR of 15% over the next four years on a consolidated basis. Growth is anticipated to step up in FY ’29 due to complex product launches. However, the Middle East conflict could impact raw material and logistics costs by 1% to 2% on revenue. Cost optimization efforts are ongoing to mitigate these impacts. GLAND plans to invest INR2,000 crores over the next three years, with INR500 crores expected in FY ’27, to ramp up GLP-1 products by 2030 and expand cartridge capacity to 140 million units.

Get all details on GLAND — P&L, peers, shareholding and more on TradeAlone.